About Biofarma
Biofarma is a company based in Bandung (Indonesia) founded in 1890. Biofarma offers products and services including Vaccines, Distribution Services, and Immunization Services. Biofarma operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and HOOKIPA Pharma, among others.
- InvestorsDanamon
& 2 more
Products & Services of Biofarma
Biofarma offers a comprehensive portfolio of products and services, including Vaccines, Distribution Services, and Immunization Services.
Production of vaccines for disease prevention and immunization.
Trade and distribution of drugs and medical devices.
Provision of vaccination and health screening programs.
Apps and channels of Biofarma
its YouTube channel Bio Farma has 174 subscribers and 30 videos.
Videos from Biofarma
The most watched videos on Biofarma's YouTube channel, Bio Farma (174 subscribers). Click a video to play it here.
More on Bio Farma.
Funding Insights of Biofarma
- Total Rounds 3
- First Round $106.61M
(Feb 2021)
- Investors Count 3
All 3 funding rounds of Biofarma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | – | Unspecified | – | – | |
| Sep 2021 | – | Debt – Conventional | – | – | |
| Feb 2021 | $106.61M | Debt – Conventional | – | – |
3 investors in total: 3 institutional.
Investors in Biofarma
Biofarma has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Danamon, Gates Foundation and HSBC Indonesia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
HSBC Indonesia is engaged in providing banking and financial services. | – | hsbc.co.id | Indonesia | |
Commercial banking services are provided nationwide by Danamon. | 1956 | danamon.co.id | Jakarta, Indonesia |
Investor details for Biofarma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biofarma
77 people are tracked at Biofarma (14 in leadership, 63 in team).
| Name | Role | Group |
|---|---|---|
Shadiq Akasya | President Director | Leadership |
Dea M. | Head Of Learning And Development | Leadership |
Acep Riza Wijayadikusumah | Head Of Research And Product Development Division | Leadership |
Lala Arief | Head Of Corporate Communications Dept. | Leadership |
Hidayat S. | VP Institutional Relationship & Medical Service Transformation | Leadership |
Fitri Puspadewi | Vice President Of Domestic Marketing & Sales | Leadership |
Dimas Auditya | Head Of Sales Domestic Department | Leadership |
Muhammad Abdul Aziz Prakoso | Senior Executive Assistant To CEO | Leadership |
Budiharto Iin Susanti | Human Capital Director | Leadership |
Erik Ismail | Head Of Dept, Vaccine Project | Leadership |
Edwin Pringadi | Head Of Domestic Marketing Communication Department | Leadership |
Fariz Pramaputra | Head Of Legal Department | Leadership |
Wening Samudrawati | Head Of Human Capital Strategic & Ihcms | Leadership |
Heri Kurniawan | Executive Assistant Of Human Capital Director | Leadership |
Latri Rahmah | Project Leader Of MR Vaccine Development; Research Sub Coordinate | Team |
Mediola Dwi Novida | Strategic Marketing Specialist | Team |
Elgiani Yassifa Yulia Nurinsani | Research And Development Staff | Team |
Dinda Khairunnisa Sabila | Research Development Staff | Team |
Arif Sadjuri | Project Leader For Hexavalent Vaccine Development | Team |
Widyandini Dwi Prastiwi | Research And Development | Team |
57 more people are available in the full profile.
Complete people profiles for Biofarma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biofarma
3 dated milestones of Biofarma across 132 years, from founding to its latest funding, stage changes and deals.
- Founded Biofarma is founded.
- Funding First funding round of $106.6M.
- Funding Latest funding round, Unspecified,.
Competitors of Biofarma
Biofarma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and HOOKIPA Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| stallergenesgreer.com | 2013 | London, United Kingdom | – | 115,499 | Allergen immunotherapies for respiratory allergies are developed. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. |
Detailed competitors of Biofarma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biofarma
The website of Biofarma (biofarma.co.id) receives about 170.9K visits a month and ranks #212,609 among all websites worldwide, #3,293 in Banking Credit and Lending.
- Monthly visits170.9K
▼ 12.5% vs previous month
- Unique visitors43K
per month
- Global rank#212,609
among all websites
- Category rank#3,293
Finance · Banking Credit and Lending
- Bounce rate30%
- Pages per visit3.7
- Average visit3 min 18 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Biofarma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kimiafarma.co.id | 100% | 1.1M | #37,869 | View details | |
| adb.org | 82% | 888.9K | #53,656 | View details | |
| pegadaian.co.id | 82% | 4.8M | #15,529 | View details | |
palyja.co.id | palyja.co.id | 74% | – | #3,251,883 | – |
| victoriabank.co.id | 74% | 9.8K | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for Biofarma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Biofarma
Complete news archive for Biofarma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Biofarma
10 companies that operate in the same segment as Biofarma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biofarma
Biofarma was founded in 1890 and raised its 1st funding round 131 years after it was founded.
Biofarma is headquartered in Bandung, Indonesia. It is registered at Bandung, West Java, Indonesia.
Biofarma was established in 1890 in Bandung, Indonesia, within the pharmaceutical sector. A variety of vaccines is produced for therapeutic areas, encompassing bacterial options such as TT, BCG, and DTP, along with viral vaccines including flu, polio, Hep B, and measles. Pentavalent combination vaccines are also made, in addition to sera for snake venom, diphtheria, and tetanus, and diagnostic products. Operations focus on these manufacturing activities.
Biofarma's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
Biofarma offers Vaccines, Distribution Services, and Immunization Services.
Biofarma has 3 investors. Key investors include Danamon, Gates Foundation, and HSBC Indonesia.
Biofarma operates through Pt Bio Farma (Persero).
The website of Biofarma receives about 171 thousand visits a month and ranks #212,609 among all websites worldwide.